Non-alcoholic Steatohepatitis
237
21
29
147
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
67 trials with published results (28%)
Research Maturity
147 completed trials (62% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
8.0%
19 terminated out of 237 trials
88.6%
+2.0% vs benchmark
9%
22 trials in Phase 3/4
46%
67 of 147 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 147 completed trials
Clinical Trials (237)
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Vitamin E Dosing Study
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Assessment of Fatty Liver With Thermo-acoustic Device
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
Identification of Liver Fibrosis Biomarkers
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Integrated Diagnostics for Early Diagnosis of Liver Disease
Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study
Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
The Olmsted NAFLD Epidemiology Study (TONES)
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)